Nicotinic acetylcholine receptors, or nAChRs, are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the postsynaptic side of the neuromuscular junction. As ionotropic receptors, nAChRs are directly linked to ion channels and do not use second messengers (as metabotropic receptors do). Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors.[1]
Like the other type of acetylcholine receptor—the muscarinic acetylcholine receptor (mAChR)—the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine —hence the name "nicotinic."[1][2][3]
In insects, the cholinergic system is limited to the central nervous system.[4] In contrast, neuronal receptors are found in both the central nervous system and the peripheral nervous system of mammals. Mammalian neuromuscular receptors are found in the neuromuscular junctions of somatic muscles; stimulation of these receptors causes muscular contraction.
Contents
- 1 Structure
- 2 Binding the channel
- 3 Opening the channel
- 4 Effects
- 5 Receptor regulation
- 5.1 Receptor desensitisation
- 6 Roles
- 7 Subunits
- 8 See also
- 9 References
- 10 External links
Structure[edit source | edit]
Nicotinic receptors, with a molecular mass of 290 kDa,[5] are made up of five subunits, arranged symmetrically around a central pore.[1] Each subunit comprises four transmembrane domains with both the N- and C-terminus located extracellularly. They possess similarities with GABAA receptors, glycine receptors, and the type 3 serotonin receptors (which are all ionotropic receptors), or the signature Cys-loop proteins.[6]
In vertebrates, nicotinic receptors are broadly classified into two subtypes based on their primary sites of expression: muscle-type nicotinic receptors and neuronal-type nicotinic receptors. In the muscle-type receptors, found at the neuromuscular junction, receptors are either the embryonic form, composed of α1, β1, δ, and γ subunits in a 2:1:1:1 ratio, or the adult form composed of α1, β1, δ, and ε subunits in a 2:1:1:1 ratio.[1][2][3][7] The neuronal subtypes are various homomeric or heteromeric combinations of twelve different nicotinic receptor subunits: α2−α10 and β2−β4. Examples of the neuronal subtypes include: (α4)3(β2)2, (α4)2(β2)3, and (α7)5. In both muscle-type and neuronal-type receptors, the subunits are somewhat similar to one another, especially in the hydrophobic regions.
Binding the channel[edit source | edit]
For ligands, see Nicotinic agonist and Nicotinic antagonist.
As with all ligand-gated ion channels, opening of the nAChR channel pore requires the binding of a chemical messenger. Several different terms are used to refer to the molecules that bind receptors, such as ligand. As well as the endogenous agonist acetylcholine, agonists of the nAChR are nicotine, epibatidine, and choline.
In muscle-type nAChRs, the acetylcholine binding sites are located at the α and either ε or δ subunits interface (or between two α subunits in the case of homomeric receptors) in the extracellular domain near the N terminus.[2][8] When an agonist binds to the site, all present subunits undergo a conformational change and the channel is opened[9] and a pore with a diameter of about 0.65 nm opens.[2]
Opening the channel[edit source | edit]
Nicotinic AChRs may exist in different interconvertible conformational states. Binding of an agonist stabilises the open and desensitised states. Opening of the channel allows positively charged ions to move across it; in particular, sodium enters the cell and potassium exits. The net flow of positively-charged ions is inward.
The nAChR is a non-selective cation channel, meaning that several different positively charged ions can cross through.[1] It is permeable to Na+ and K+, with some subunit combinations that are also permeable to Ca2+.[2][10][11] The amount of sodium and potassium the channels allow through their pores (their conductance) varies from 50–110 pS, with the conductance depending on the specific subunit composition as well as the permeant ion.[12]
It is interesting to note that, because some neuronal nAChRs are permeable to Ca2+, they can affect the release of other neurotransmitters.[3] The channel usually opens rapidly and tends to remain open until the agonist diffuses away, which usually takes about 1 millisecond.[2] However, AChRs can sometimes open with only one agonist bound and, in rare cases, with no agonist bound, and they can close spontaneously even when ACh is bound. Therefore, ACh binding creates only a probability of pore opening, which increases as more ACh binds.[9]
The nAChR is unable to bind ACh when bound to any of the snake venom α-neurotoxins. These α-neurotoxins antagonistically bind tightly and noncovalently to nAChRs of skeletal muscles, thereby blocking the action of ACh at the postsynaptic membrane, inhibiting ion flow and leading to paralysis and death. The nAChR contains two binding sites for snake venom neurotoxins. Progress towards discovering the dynamics of binding action of these sites has proved difficult, although recent studies using normal mode dynamics[13] have aided in predicting the nature of both the binding mechanisms of snake toxins and of ACh to nAChRs. These studies have shown that a twist-like motion caused by ACh binding is likely responsible for pore opening, and that one or two molecules of α-bungarotoxin (or other long-chain α-neurotoxin) suffice to halt this motion. The toxins seem to lock together neighboring receptor subunits, inhibiting the twist and therefore, the opening motion.[14]
Effects[edit source | edit]
The activation of receptors by nicotine modifies the state of neurons through two main mechanisms. On one hand, the movement of cations causes a depolarization of the plasma membrane (which results in an excitatory postsynaptic potential in neurons), but also by the activation of voltage-gated ion channels. On the other hand, the entry of calcium acts, either directly or indirectly, on different intracellular cascades leading, for example, to the regulation of the activity of some genes or the release of neurotransmitters.
Receptor regulation[edit source | edit]
Receptor desensitisation[edit source | edit]
Ligand-bound desensitisation of receptors was first characterised by Katz and Thesleff in the nicotinic acetylcholine receptor.[15]
Prolonged or repeat exposure to a stimulus often results in decreased responsiveness of that receptor toward a stimulus, termed desensitisation (for example: myasthenia gravis). nAChR function can be modulated by phosphorylation[16] by the activation of second messenger-dependent protein kinases. PKA[15] and PKC[17] have been shown to phosphorylate the nAChR resulting in its desensitisation. It has been reported that, after prolonged receptor exposure to the agonist, the agonist itself causes an agonist-induced conformational change in the receptor, resulting in receptor desensitisation.[18] This receptor desensitisation has been previously modeled in the context of a two-state mathematical model (see this link [1]) Desensitised receptors can revert to a prolonged open state when an agonist is bound in the presence of a positive allosteric modulator, for example PNU-120596.[19]
Roles[edit source | edit]
The subunits of the nicotinic receptors belong to a multigene family (16 members in humans) and the assembly of combinations of subunits results in a large number of different receptors (for more information see the Ligand-Gated Ion Channel database). These receptors, with highly variable kinetic, electrophysiological and pharmacological properties, respond differently to nicotine, at very different effective concentrations. This functional diversity allows them to take part in two major types of neurotransmission. Classical synaptic transmission (wiring transmission) involves the release of high concentrations of neurotransmitter, acting on immediately neighboring receptors. In contrast, paracrine transmission (volume transmission) involves neurotransmitters released by synaptic buttons, which then diffuse through the extra-cellular medium until they reach their receptors, which may be distant. Nicotinic receptors can also be found in different synaptic locations; for example the muscle nicotinic receptor always functions post-synaptically. The neuronal forms of the receptor can be found both post-synaptically (involved in classical neurotransmission) and pre-synaptically[20] where they can influence the release of multiple neurotransmitters.
Subunits[edit source | edit]
To date, 17 nAChR subunits have been identified, which are divided into muscle-type and neuronal-type subunits. Of these 17 subunits, α2−α7, and β2−β4 have been cloned in humans, the remaining genes identified in chick and rat genomes.[21]
The nAChR subunits have been divided into 4 subfamilies (I-IV) based on similarities in protein sequence.[22] In addition, subfamily III has been further divided into 3 tribes.
| Neuronal-type |
Muscle-type |
| I |
II |
III |
IV |
| α9, α10 |
α7, α8 |
1 |
2 |
3 |
α1, β1, δ, γ, ε |
| α2, α3, α4, α6 |
β2, β4 |
β3, α5 |
- α genes: CHRNA1 (muscle), CHRNA2 (neuronal), CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA8, CHRNA9, CHRNA10
- β genes: CHRNB1 (muscle), CHRNB2 (neuronal), CHRNB3, CHRNB4
- Other genes: CHRND (delta), CHRNE (epsilon), CHRNG (gamma)
Notable variations[edit source | edit]
Nicotinic receptors are pentamers of these subunits; i.e., each receptor contains five subunits. Thus, there is an immense potential of variation of the aforementioned subunits. However, some of them are more notable than others, to be specific, (α1)2β1δε (muscle-type), (α3)2(β4)3 (ganglion-type), (α4)2(β2)3 (CNS-type) and (α7)5 (another CNS-type).[23] A comparison follows:
| Receptor-type |
Location |
Effect |
Nicotinic agonists |
Nicotinic antagonists |
Muscle-type:
(α1)2β1δε[23]
or
(α1)2β1δγ |
Neuromuscular junction |
EPSP, mainly by increased Na+ and K+ permeability |
- acetylcholine[1]
- carbachol
- suxamethonium
|
- α-bungarotoxin[24]
- α-conotoxin
- tubocurarine[1]
- pancuronium
- atracurium*
|
Ganglion-type:
(α3)2(β4)3 |
autonomic ganglia |
EPSP, mainly by increased Na+ and K+ permeability |
- acetylcholine[1]
- carbachol
- nicotine[1]
- epibatidine
- dimethylphenylpiperazinium
|
- mecamylamine[1][24]
- trimetaphan
- hexamethonium
- bupropion
- ibogaine
- 18-methoxycoronaridine
- Dextromethorphan
|
Heteromeric CNS-type:
(α4)2(β2)3 |
Brain |
Post- and presynaptic excitation,[23] mainly by increased Na+ and K+ permeability |
- nicotine
- epibatidine
- acetylcholine
- cytisine
- varenicline
|
- mecamylamine
- methylcaconitine
- α-conotoxin
- Dextromethorphan
|
Further CNS-type:
(α3)2(β4)3
|
Brain |
Post- and presynaptic excitation |
- nicotine
- epibatidine
- acetylcholine
- cytisine
|
- hexamethonium
- mecamylamine
- tubocurarine
- Dextromethorphan
|
Homomeric CNS-type:
(α7)5
|
Brain |
Post- and presynaptic excitation,[23] mainly by increased Ca2+ permeability |
- epibatidine
- dimethylphenylpiperazinium
- varenicline [25]
|
- mecamylamine
- memantine
- amantadine
- α-bungarotoxin[1]
- Dextromethorphan
|
See also[edit source | edit]
- Drug Discovery and Development: Nicotinic Acetylcholine Receptor Agonists
References[edit source | edit]
- ^ a b c d e f g h i j k Purves, Dale, George J. Augustine, David Fitzpatrick, William C. Hall, Anthony-Samuel LaMantia, James O. McNamara, and Leonard E. White (2008). Neuroscience (4th ed.). Sinauer Associates. pp. 122–6. ISBN 978-0-87893-697-7.
- ^ a b c d e f Siegel G.J., Agranoff B.W., Fisher S.K., Albers R.W., and Uhler M.D. (1999). "Basic Neurochemistry: Molecular, Cellular and Medical Aspects". GABA Receptor Physiology and Pharmacology (6th ed.). American Society for Neurochemistry. Retrieved 2008-10-01.
- ^ a b c Itier V, Bertrand D (August 2001). "Neuronal nicotinic receptors: from protein structure to function". FEBS Letters 504 (3): 118–25. doi:10.1016/S0014-5793(01)02702-8. PMID 11532443.
- ^ Yamamoto, Izuru (1999). "Nicotine to Nicotinoids: 1962 to 1997". In Yamamoto, Izuru; Casida, John. Nicotinoid Insecticides and the Nicotinic Acetylcholine Receptor. Tokyo: Springer-Verlag. pp. 3–27
- ^ Unwin N. (March 4, 2005). "Refined structure of the nicotinic acetylcholine receptor at 4A resolution". Journal of Molecular Biology 346 (4): 967–89. doi:10.1016/j.jmb.2004.12.031. PMID 15701510.
- ^ Cascio, M. (May 7, 2004). "Structure and function of the glycine receptor and related nicotinicoid receptors". Journal of Biological Chemistry 279 (19): 19383–6. doi:10.1074/jbc.R300035200. PMID 15023997.
- ^ Giniatullin R, Nistri A, Yakel JL (July 2005). "In muscle, the acetylcholine ligand binds to two regions, one region is between the alpha and delta subunits and the other, between the alpha and gamma subunits. Desensitisation of nicotinic ACh receptors: shaping cholinergic signaling". Trends Neurosci. 28 (7): 371–8. doi:10.1016/j.tins.2005.04.009. PMID 15979501.
- ^ Squire, Larry (2003). Fundamental neuroscience (2nd ed.). Amsterdam: Acad. Press. p. 1426. ISBN 978-0-12-660303-3.
- ^ a b Colquhoun D, Sivilotti LG. (June 2004). "Function and structure in glycine receptors and some of their relatives". Trends Neurosci. 27 (6): 337–44. doi:10.1016/j.tins.2004.04.010. PMID 15165738.
- ^ Beker F, Weber M, Fink RH, Adams DJ (September 2003). "Muscarinic and nicotinic ACh receptor activation differentially mobilize Ca2+ in rat intracardiac ganglion neurons". J. Neurophysiol. 90 (3): 1956–64. doi:10.1152/jn.01079.2002. PMID 12761283.
- ^ Weber M, Motin L, Gaul S, Beker F, Fink RH, Adams DJ (January 2005). "Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons". Br. J. Pharmacol. 144 (1): 98–107. doi:10.1038/sj.bjp.0705942. PMC 1575970. PMID 15644873.
- ^ Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B (22–28 May 1986). "Molecular distinction between fetal and adult forms of muscle acetylcholine receptor". Nature 321 (6068): 406–11. doi:10.1038/321406a0. PMID 2423878.
- ^ Levitt, M.; Sander, C.; Stern, P. S. (1985). "Protein normal-mode dynamics: Trypsin inhibitor, crambin, ribonuclease and lysozyme". Journal of Molecular Biology 181 (3): 423–447. doi:10.1016/0022-2836(85)90230-X. PMID 2580101. edit
- ^ Samson, A. O.; Levitt, M. (2008). "Inhibition Mechanism of the Acetylcholine Receptor by α-Neurotoxins as Revealed by Normal-Mode Dynamics". Biochemistry 47 (13): 4065–4070. doi:10.1021/bi702272j. PMC 2750825. PMID 18327915. edit
- ^ a b Pitchford S, Day JW, Gordon A, Mochly-Rosen D (November 1992). "Nicotinic acetylcholine receptor desensitisation is regulated by activation-induced extracellular adenosine accumulation". Journal of Neuroscience 12 (11): 4540–4. PMID 1331363.
- ^ Huganir RL, Greengard P (February 1983). "cAMP-dependent protein kinase phosphorylates the nicotinic acetylcholine receptor". Proceedings of the National Academy of Sciences of the United States of America 80 (4): 1130–4. doi:10.1073/pnas.80.4.1130. PMC 393542. PMID 6302672.
- ^ Safran A, Sagi-Eisenberg R, Neumann D, Fuchs S (August 1987). "Phosphorylation of the acetylcholine receptor by protein kinase C and identification of the phosphorylation site within the receptor delta subunit". The Journal of Biological Chemistry 262 (22): 10506–10. PMID 3038884.
- ^ Barrantes FJ (September 1978). "Agonist-mediated changes of the acetylcholine receptor in its membrane environment". Journal of Molecular Biology 124 (1): 1–26. doi:10.1016/0022-2836(78)90144-4. PMID 712829.
- ^ Hurst RS; Hajós, M; Raggenbass, M; Wall, TM; Higdon, NR; Lawson, JA; Rutherford-Root, KL; Berkenpas, MB et al. (April 2005). "A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization". Journal of Neuroscience 25 (17): 4396–405. doi:10.1523/JNEUROSCI.5269-04.2005. PMID 15858066.
- ^ Wonnacott S (February 1997). "Presynaptic nicotinic ACh receptors". Trends in neurosciences 20 (2): 92–8. doi:10.1016/S0166-2236(96)10073-4. PMID 9023878.
- ^ Graham A, Court JA, Martin-Ruiz CM, Jaros E, Perry R, Volsen SG, Bose S, Evans N, Ince P, Kuryatov A, Lindstrom J, Gotti C, Perry EK (2002). "Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum". Neuroscience 113 (3): 493–507. doi:10.1016/S0306-4522(02)00223-3. PMID 12150770.
- ^ Le Novère N, Changeux JP (February 1995). "Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells". Journal of molecular evolution 40 (2): 155–72. doi:10.1007/BF00167110. PMID 7699721.
- ^ a b c d Rang, H. P. (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4.
- ^ a b Neurosci.pharm - MBC 3320 Acetylcholine
- ^ Mihalak KB, Carroll FI, Luetje CW (2006). "Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors". Mol. Pharmacol. 70 (3): 801–805. doi:10.1124/mol.106.025130. PMID 16766716.
External links[edit source | edit]
- Calculated spatial position of Nicotinic acetylcholine receptor in the lipid bilayer
|
Antigens: Autoantigens
|
|
| Dehydrogenase |
- Branched-chain alpha-keto acid dehydrogenase complex
- Oxoglutarate dehydrogenase
- Pyruvate dehydrogenase
|
|
| Transglutaminase |
- Epidermal transglutaminase
- Tissue transglutaminase
|
|
| Nucleoporins |
- NUP35
- NUP37
- NUP43
- NUP50
- NUP54
- NUP62
- NUP85
- NUP88
- NUP93
- NUP98
- NUP107
- NUP133
- NUP153
- NUP155
- NUP160
- NUP188
- NUP210
- NUP205
- NUP214
|
|
| Other |
- Acetylcholine receptor
- Actin
- Apolipoprotein H
- Cardiolipin
- Centromere
- Filaggrin (Citrullinate)
- Gangliosides
- Sp100 nuclear antigen
- Thrombin
- Topoisomerase
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
|
Ion channel, cell surface receptor: ligand-gated ion channels
|
|
| Cys-loop receptors |
|
5-HT/serotonin
|
|
|
|
GABA
|
- GABAA
- α1
- α2
- α3
- α4
- α5
- α6
- β1
- β2
- β3
- γ1
- γ2
- γ3
- δ
- ε
- π
- θ
- GABAA-ρ
|
|
|
Glycine
|
|
|
|
Nicotinic acetylcholine
|
- monomers: α1
- α2
- α3
- α4
- α5
- α6
- α7
- α9
- α10
- β1
- β2
- β3
- β4
- δ
- ε
- pentamers: (α3)2(β4)3
- (α4)2(β2)3
- (α7)5
- (α1)2(β4)3 - Ganglion type
- (α1)2β1δε - Muscle type
|
|
|
Zinc
|
|
|
|
| Ionotropic glutamates |
|
Ligand-gated only
|
|
|
|
Voltage- and ligand-gated
|
- NMDA
- 1
- 2A
- 2B
- 2C
- 2D
- 3A
- 3B
- L1A
- L1B
|
|
|
‘Orphan’
|
|
|
|
| ATP-gated channels |
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Cholinergics
|
|
|
Receptor ligands
|
|
|
mAChR
|
- Agonists: 77-LH-28-1
- AC-42
- AC-260,584
- Aceclidine
- Acetylcholine
- AF30
- AF150(S)
- AF267B
- AFDX-384
- Alvameline
- AQRA-741
- Arecoline
- Bethanechol
- Butyrylcholine
- Carbachol
- CDD-0034
- CDD-0078
- CDD-0097
- CDD-0098
- CDD-0102
- Cevimeline
- Choline
- cis-Dioxolane
- Ethoxysebacylcholine
- LY-593,039
- L-689,660
- LY-2,033,298
- McNA343
- Methacholine
- Milameline
- Muscarine
- NGX-267
- Ocvimeline
- Oxotremorine
- PD-151,832
- Pilocarpine
- RS86
- Sabcomeline
- SDZ 210-086
- Sebacylcholine
- Suberylcholine
- Talsaclidine
- Tazomeline
- Thiopilocarpine
- Vedaclidine
- VU-0029767
- VU-0090157
- VU-0152099
- VU-0152100
- VU-0238429
- WAY-132,983
- Xanomeline
- YM-796
Antagonists: 3-Quinuclidinyl Benzilate
- 4-DAMP
- Aclidinium Bromide
- Anisodamine
- Anisodine
- Atropine
- Atropine Methonitrate
- Benactyzine
- Benzatropine/Benztropine
- Benzydamine
- BIBN 99
- Biperiden
- Bornaprine
- CAR-226,086
- CAR-301,060
- CAR-302,196
- CAR-302,282
- CAR-302,368
- CAR-302,537
- CAR-302,668
- CS-27349
- Cyclobenzaprine
- Cyclopentolate
- Darifenacin
- DAU-5884
- Dimethindene
- Dexetimide
- DIBD
- Dicyclomine/Dicycloverine
- Ditran
- EA-3167
- EA-3443
- EA-3580
- EA-3834
- Etanautine
- Etybenzatropine/Ethylbenztropine
- Flavoxate
- Himbacine
- HL-031,120
- Ipratropium bromide
- J-104,129
- Hyoscyamine
- Mamba Toxin 3
- Mamba Toxin 7
- Mazaticol
- Mebeverine
- Methoctramine
- Metixene
- N-Ethyl-3-Piperidyl Benzilate
- N-Methyl-3-Piperidyl Benzilate
- Orphenadrine
- Otenzepad
- Oxybutynin
- PBID
- PD-102,807
- PD-0298029
- Phenglutarimide
- Phenyltoloxamine
- Pirenzepine
- Piroheptine
- Procyclidine
- Profenamine
- RU-47,213
- SCH-57,790
- SCH-72,788
- SCH-217,443
- Scopolamine/Hyoscine
- Solifenacin
- Telenzepine
- Tiotropium bromide
- Tolterodine
- Trihexyphenidyl
- Tripitamine
- Tropatepine
- Tropicamide
- WIN-2299
- Xanomeline
- Zamifenacin; Others: 1st Generation Antihistamines (Brompheniramine
- chlorphenamine
- cyproheptadine
- dimenhydrinate
- diphenhydramine
- doxylamine
- mepyramine/pyrilamine
- phenindamine
- pheniramine
- tripelennamine
- triprolidine, etc)
- Tricyclic Antidepressants (Amitriptyline
- doxepin
- trimipramine, etc)
- Tetracyclic Antidepressants (Amoxapine
- maprotiline, etc)
- Typical Antipsychotics (Chlorpromazine
- thioridazine, etc)
- Atypical Antipsychotics (Clozapine
- olanzapine, etc.)
|
|
|
nAChR
|
- Agonists: 5-HIAA
- A-84,543
- A-366,833
- A-582,941
- A-867,744
- ABT-202
- ABT-418
- ABT-560
- ABT-894
- Acetylcholine
- Altinicline
- Anabasine
- Anatoxin-a
- AR-R17779
- Butinoline
- Butyrylcholine
- Carbachol
- Choline
- Cotinine
- Cytisine
- Decamethonium
- Desformylflustrabromine
- Dianicline
- Dimethylphenylpiperazinium
- Epibatidine
- Epiboxidine
- Ethanol
- Ethoxysebacylcholine
- EVP-4473
- EVP-6124
- Galantamine
- GTS-21
- Ispronicline
- Lobeline
- MEM-63,908/RG-3487
- Nicotine
- NS-1738
- PHA-543,613
- PHA-709,829
- PNU-120,596
- PNU-282,987
- Pozanicline
- Rivanicline
- RJR-2429
- Sazetidine A
- Sebacylcholine
- SIB-1508Y
- SIB-1553A
- SSR-180,711
- Suberylcholine
- Suxamethonium/Succinylcholine
- TC-1698
- TC-1734
- TC-1827
- TC-2216
- TC-5214
- TC-5619
- TC-6683
- Tebanicline
- Tropisetron
- UB-165
- Varenicline
- WAY-317,538
- XY-4083
Antagonists: 18-Methoxycoronaridine
- α-Bungarotoxin
- α-Conotoxin
- Alcuronium
- Amantadine
- Anatruxonium
- Atracurium
- Bupropion
- Chandonium
- Chlorisondamine
- Cisatracurium
- Coclaurine
- Coronaridine
- Dacuronium
- Decamethonium
- Dextromethorphan
- Dextropropoxyphene
- Dextrorphan
- Diadonium
- DHβE
- Dimethyltubocurarine/Metocurine
- Dipyrandium
- Dizocilpine/MK-801
- Doxacurium
- Duador
- Esketamine
- Fazadinium
- Gallamine
- Hexafluronium
- Hexamethonium/Benzohexonium
- Ibogaine
- Isoflurane
- Ketamine
- Kynurenic acid
- Laudexium/Laudolissin
- Levacetylmethadol
- Malouetine
- Mecamylamine
- Memantine
- Methadone (Levomethadone)
- Methorphan/Racemethorphan
- Methyllycaconitine
- Metocurine
- Mivacurium
- Morphanol/Racemorphan
- Neramexane
- Nitrous Oxide
- Pancuronium
- Pempidine
- Pentamine
- Pentolinium
- Phencyclidine
- Pipecuronium
- Radafaxine
- Rapacuronium
- Rocuronium
- Surugatoxin
- Thiocolchicoside
- Toxiferine
- Trimethaphan
- Tropeinium
- Tubocurarine
- Vecuronium
- Xenon
|
|
|
|
|
Reuptake inhibitors
|
|
|
Plasmalemmal
|
|
CHT Inhibitors
|
- Hemicholinium-3/Hemicholine
- Triethylcholine
|
|
|
|
Vesicular
|
|
|
|
|
|
Enzyme inhibitors
|
|
|
Anabolism
|
|
ChAT inhibitors
|
- 1-(-Benzoylethyl)pyridinium
- 2-(α-Naphthoyl)ethyltrimethylammonium
- 3-Chloro-4-stillbazole
- 4-(1-Naphthylvinyl)pyridine
- Acetylseco hemicholinium-3
- Acryloylcholine
- AF64A
- B115
- BETA
- CM-54,903
- N,N-Dimethylaminoethylacrylate
- N,N-Dimethylaminoethylchloroacetate
|
|
|
|
Catabolism
|
|
AChE inhibitors
|
|
|
|
BChE inhibitors
|
- Cymserine * Many of the acetylcholinesterase inhibitors listed above act as butyrylcholinesterase inhibitors.
|
|
|
|
|
|
Others
|
|
|
Precursors
|
- Choline (Lecithin)
- Citicoline
- Cyprodenate
- Dimethylethanolamine
- Glycerophosphocholine
- Meclofenoxate/Centrophenoxine
- Phosphatidylcholine
- Phosphatidylethanolamine
- Phosphorylcholine
- Pirisudanol
|
|
|
Cofactors
|
- Acetic acid
- Acetylcarnitine
- Acetyl-coA
- Vitamin B5 (Pantethine
- Pantetheine
- Panthenol)
|
|
|
Others
|
- Acetylcholine releasing agents: α-Latrotoxin
- β-Bungarotoxin; Acetylcholine release inhibitors: Botulinum toxin (Botox); Acetylcholinesterase reactivators: Asoxime
- Obidoxime
- Pralidoxime
|
|
|
|